

The curricula vitae of the board of directors nominees

Kenneth Charhut (1958) has been a member of the board of directors since 2013. Mr Charhut is a board member of Reshape Medical and Foldax Inc; CEO and President of Compellon Inc; director of Folda LLC; independent board member of Avencina LLC; and a board member of the NHS Investment Committee. Previously Mr. Charhut was CEO and President of MindFrame Inc and Orgis Medical. He spent 16 years at Baxter Healthcare Corporation, and is a former independent director of Arges Medical and Micro Dexterity Systems. Mr. Charhut has served on a number of industry councils in the U.S. and Japan. He holds a B.Sc. in mechanical engineering from Cornell University and an MBA from the University of Chicago.

Johan Christenson (1958) joined the board of directors in 2007. He is also a member of the board at Cerenis SA, Trimb AB, Oncopeptides AB, Oncos Therapeutics Oy, Ancilla AB and Benechill Inc. Christenson is a partner at HealthCap. Prior to joining Odlander Fredrikson, Mr. Christenson worked at SEB Företagsinvest. Astra and AstraZeneca. He has lectured in neuroscience and is the author of 17 scientific articles. Mr. Christenson was assistant dean at the Karolinska Institute Graduate School. He received his medical training at the Karolinska Institute and has a Ph.D. in neuroscience.

Olli Riikkala (1951) has been a member of the board of directors since 2007 and deputy chairman. Mr. Riikkala is a member of the board of directors of the following private healthcare companies: Cancer Hospital Docrates Oy, MediXine Oy, Mendor Oy, Optomeditech Oy and Biomedicum foundation. He has served 26 consecutive years in publicly listed company board of directors including Oriola-KD Oyj as chairman. Mr. Riikkala worked at Instrumentarium Oyj during years 1979 – 2003 in various executive positions of which last 6 years as CEO. After that he served 3.5 years as President of GE Healthcare IT EMEA. Mr. Riikkala holds a M.Sc. in engineering from the Helsinki University of Technology, a M.Sc. in economics from Helsinki School of Economics and an MBA from Claremont Graduate University.

Ekaterina Smirnyagina (1966) joined the board of directors in 2013. Dr. Smirnyagina is a partner at the Capricorn Health-Tech Fund Venture Fund. Prior to this she was with Alta Partners, a US healthcare focus venture fund. Her current and past board memberships include Adocia (Euronext: ADOC.PA), iSTAR Medical SA, Ablynx (Euronext: ABLX.BE), Cerenis Therapeutics SA, Innate Pharma (Euronext: IPH.PA) and Kiadis Pharma NV. Previously Dr. Smirnyagina worked in business development at Genset S.A. and management consulting at the Mitchell Madison Group. She was a postdoctoral fellow in microbiology & immunology at the Stanford University School of Medicine and holds a Ph.D. in cellular & molecular biology from the University of Wisconsin-Madison and a B.Sc. in biochemistry from Moscow State University.

Juha Vapaavuori (1952) has been a member of the board of directors since 2006. Mr. Vapaavuori is chairman of the board of directors of KC-Holding 3 Oy, a member of the board of FIT Biotech Oy and Vivoxid Oy and is Senior Lead of corporate finance at the Finnish Innovation Fund Sitra. He previously served as a board member of Pharmatory Oy. Mr. Vapaavuori holds an M.A. from University of Helsinki.

René Kuijten joined the board of directors in 2007. Mr. Kuijten is general partner and co-owner of Life Sciences Partners and has been a member of the board of several of its portfolio companies. Mr. Kuijten was previously senior engagement manager at McKinsey & Co and leader of its European Health Care and Pharmaceuticals Practice. He is an advisory board member of Pivot Park, a member of Regiegroep Topsector Life Sciences & Health and a board member of the Dutch Venture Capital Association. Mr. Kuijten was a WHO research fellow at the University of Pennsylvania, and has a Ph.D. in medicine from the University of Amsterdam, an MBA from INSEAD, and an MD and M.Sc. in medicine from the University of Utrecht.

Juliet Thompson (1966) is nominated as a new board member. Mrs. Thompson was founding partner of Code Securities, healthcare and cleantech investment banking boutique and was key to its successful sale to Nomura two years later. She has significant leadership experience currently heading the healthcare team at Oriel and previously having been Managing Director of Corporate Finance at Nomura Code. Juliet was also an Executive Director on the Board of Nomura Code Securities Ltd. She is a chartered Accountant ACA; Chartered Institute for Securities (ASCI); BSc Economics (Bristol University).